Key result
The COVIVA study is a prospective cohort and nested randomized controlled trial designed to evaluate ivabradine for postural orthostatic tachycardia syndrome in patients with long-haul COVID-19, with no results reported yet.
Why the study?
Long-haul COVID-19 shares symptoms with POTS and IST, but optimal therapies for associated dysautonomia remain undefined.
Does ivabradine improve symptoms and reduce heart rate in patients with long-haul COVID-19 associated POTS or IST?
Does ivabradine improve symptoms and reduce heart rate in patients with long-haul COVID-19 associated POTS or IST?
This study protocol outlines a comprehensive evaluation of long-haul COVID-19 and a nested randomized trial to assess whether ivabradine improves heart rate and symptoms in patients with post-COVID POTS or IST.
Answers are grounded in this paper and cite their sources.
May support ivabradine for post-COVID POTS/IST symptoms; extends small prior RCTs but needs larger outcome trials.
Background: Significant clinical similarities have been observed between the recently Described ‘Long-Haul’ COVID-19 (LHC) syndrome, Postural Orthostatic Tachycardia Syndrome (POTS) and Inappropriate Sinus Tachycardia (IST). Shared symptoms include light-headedness, palpitations, tremulousness, generalized weakness, blurred vision, chest pain, dyspnea, “brain-fog”, and fatigue. Ivabradine is a selective sinoatrial node blocker FDA-approved for management of tachycardia associated with stable angina and heart failure not fully managed by beta blockers. In our study we aim to identify risk factors underlying LHC, as well as the effectiveness of ivabradine in controlling heart rate dysregulations and POTS/IST related symptoms. Methods/Design: A detailed prospective phenotypic evaluation combined with multi-omic analysis of 200 LHC volunteers will be conducted to identify risk factors for autonomic dysfunction. A comparator group of 50 volunteers with documented COVID-19 but without LHC will be enrolled to better understand the risk factors for LHC and autonomic dysfunction. Those in the cohort who meet diagnostic criteria for POTS or IST will be included in a nested prospective, randomized, placebo-controlled trial to assess the impact of ivabradine on symptoms and heart rate, assessed non-invasively based on physiologic response and ambulatory electrocardiogram. Additionally, studies on catecholamine production, mast cell and basophil degranulation, inflammatory biomarkers, and indicators of metabolic dysfunction will be measured to potentially provide molecular classification and mechanistic insights. Discussion: Optimal therapies for dysautonomia, particularly associated with LHC, have yet to be defined. In the present study, ivabradine, one of numerous proposed interventions, will be systematically evaluated for therapeutic potential in LHC-associated POTS and IST. Additionally, this study will further refine the characteristics of the LHC-associated POTS/IST phenotype, genotype and transcriptional profile, including immunologic and multi-omic analysis of persistent immune activation and dysregulation. The study will also explore and identify potential endotheliopathy and abnormalities of the clotting cascade. Trial registration: ClinicalTrials.gov, ID: NCT05481177 Registered on 29 July 2022.
No takes yet. Share an insight, caveat, or question.
Saunders et al. (2023) studied Long-Haul COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Inappropriate Sinus Tachycardia (IST) (n=250). Ivabradine vs. Placebo was evaluated on Proportion of volunteers diagnosed with POTS or IST, and reduction of heart rate and POTS symptoms in the nested RCT. The COVIVA study is a prospective cohort and nested randomized controlled trial designed to evaluate ivabradine for postural orthostatic tachycardia syndrome in patients with long-haul COVID-19, with no results reported yet.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: